SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as community members highlight bullish price action and speculate about future growth potential. Conversations mention the potential for significant gains and the coin's strong community support. Some users are drawing comparisons to other meme coins on Solana, suggesting a broader interest in the sector.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as community members highlight its long-term development on the Solana blockchain and its listing on the Jupiter Strict List. The community is actively using the project's namesake punchline and comparing it to other popular meme coins like $DOGE.X and $SHIB.X, suggesting it could be the next big meme coin.

TOSHI

TOSHI.X is trending as the community rallies around the meme coin, anticipating significant gains and a potential Binance listing soon. Bullish sentiment is fueled by recent listings, the coin's association with Coinbase, and its status as the 'face of base'. Traders are closely watching for a breakout, with some suggesting a coordinated buy to propel the price higher.

Nyvo is a cutting-edge platform that allows anyone to create fully functional decentralized applications (dApps) using simple natural language prompts. In other words, users describe the app they want in plain English, and Nyvo’s AI-driven engine automatically generates both the on-chain smart contract backend and the web-based frontend, delivering a live blockchain application within minutes. This “prompt-to-dApp” approach dramatically lowers the barriers to Web3 development by removing the need to write code or navigate complex developer tools.The result is that developers, entrepreneurs, and even non-technical users can go from an idea to a deployed dApp faster and easier than ever before.

Nyvo

Nyvo ($NYVO.X) is trending as social media buzz points to strong chart momentum and a potential breakout. The crypto community is signaling a 'buy now' opportunity, anticipating a rapid price increase. Conversations evoke a sense of urgency, suggesting a 'rocket' is about to launch.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community anticipates upcoming revenue figures and discusses treasury mechanics.  Enthusiasm is building around its real-world asset (RWA) adoption and potential for significant growth. Some users are also discussing potential integrations with other tokens.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

$GASS.X is trending as community members highlight its potential, drawing comparisons to $PEPE.X due to its connection with creator Matt Furie, and some are pointing to a recent listing. Community members are actively discussing holding for long-term gains, emphasizing accumulation during dips, and expressing excitement about the project's future.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to the formation of its board and after-hours trading activity. However, some investors are concerned about a dilutive deal involving warrants without a lock-up period. The community is actively discussing the potential impact of these factors on the stock's price.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

$BOB.X is gaining attention, with community members highlighting its potential for a squeeze and comparing it favorably to other cryptocurrencies. The upcoming halving event and its association with $ICP.X are key points of discussion, with some suggesting it could be the next $BTC.X. Community sentiment is very bullish.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Therapeutics Inc

Cullinan Oncology Inc

Cullinan Oncology is trending due to analyst upgrades and upcoming presentations at the ASCO and other medical conferences, highlighting data related to their cancer treatment pipeline. Community members are actively discussing the company's valuation, pipeline potential, and recent insider trading activity. A recent analysis comparing CGEM to a competitor, BDTX, is also circulating.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is trending with community members expressing bullish sentiment and urging others to buy in before a potential surge. Conversations highlight the token's strong community and potential for significant gains, with some drawing comparisons to other successful meme coins. The broader discussion includes the potential for 'short squeeze' and the presence of 'big names' within the community.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?

The mean of analysts' price targets for Mersana Therapeutics (MRSN) points to a 314.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Mersana Therapeutics (MRSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +29.82% and +181.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 0.00% and -62.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Mersana Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$7.57
Prev Close	$7.17
Open	$7.22
Dividend Yield	0.00%
50-Day Moving Average	$7.34
Beta	1.92
Avg. Volume	98,416.71
PE Ratio	-0.51

52-Week High	$70.75
52-Week Low	$5.21
Market Capitalization	$37.78M
EPS (Annual)	-$14.12
Price to Book	-0.71
Revenue Per Employee	$397,029.41
Enterprise Value/EBITDA	N/A

MRSN
Mersana Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRSN News

MRSN Mersana Therapeutics Inc